Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
Items 501–560 of 560
Tomoyasu, M., Kim‐Kaneyama, J., Kohashi, K., Shinmura, K., Nogi, Y., Terasaki, M., Nagashima, M., Miyazaki, A., & Hirano, T. (2014) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.26.191
Mohamed, M. E. (2014) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2014.47019
“The attenuation was associated with reduced monocyte/macrophage accumulation in the arterial wall indicating that suppression of vascular inflammation may represent another direct cardiovascular benefit of incretin-based therapy [40].”
BackgroundPriority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
Yarek-Martynova, I. R., & Bolotskaya, L. L. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-5830
Role of GLP-1 receptor agonists in endothelial function
Erdogdu, Ö. (2012) · Figshare
Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors
Htike, Z. Z., Khunti, K., & Davies, M. J. (2012) · Clinical Practice · doi:10.2217/cpr.11.132
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
The effects of DPP-4 inhibitors on vascular endothelial function in diabetes
Salheen, S. M. (2015) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27591369
Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
TOMKIN, G. H. (2014) · Pharmaceutical Regulatory Affairs Open Access · doi:10.4172/2167-7689.1000114
GLP 1 and Macrovascular Complications
Sleiman, D. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s4-007 · Cited by 1
“5 years had maintained reductions in weight, systolic blood pressure, TG that reverted to baseline levels 6 months post exenatide cessation [37].”
BackgroundThe Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era
Kendall, D. M. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42866-6
The Role of the Glucagon-like Peptide-1 Receptor in Atherosclerosis
Panjwani, N. (2013) · TSpace (University of Toronto)
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“However, the mechanism is likely to be independent of activation of the MC4R as studies using a MC4R antagonist (AgRP(83-132) did not attenuate GLP-1’s anorectic effect(111).”
BackgroundWells, A. J. (2015) · Journal of International Crisis and Risk Communication Research
Aragão, G. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-09032017-123135
Jeong, I. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.1.32
Cardiovascular Outcomes with Liraglutide: An Update following LEADER
Ghosh, R. (2017) · Open Access Journal of Cardiology · doi:10.23880/oajc-16000101
Koshibu, M., Mori, Y., Kushima, H., Hiromura, M., Kohashi, K., Terasaki, M., Osaka, N., Fujikawa, T., Fukui, T., & Hirano, T. (2019) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.31.115
Incretin-based treatment of diabetes and cardiovascular complications
Haluzík, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.012
GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes
Almutairi, M. G. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhr3-cr50
Zarandi-Miandoab, L., Chaparzadeh, N., & Fekri-Shali, H. (2021) · Nova Biologica Reperta · doi:10.52547/nbr.8.2.130
Obesity, Metabolic Syndrome and Inflammation
Lee, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-86684-6_7
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1027
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
Unveiling the prevalence and impact of diabetes on COVID-19
Banik, S. P., Bhattacharyya, M., Ghosh, R., Chatterjee, T., & Basak, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00045-x
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Horii, T., Oikawa, Y., Kidowaki, K., Shimada, A., & Mihara, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14284
Exploring Endothelial Injury Syndromes: Mechanisms, Markers, and Therapeutic Potential
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7154-5
Watada, H. (2010) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.99.2110
Self-citationVargas-Sánchez, K., Vargas, L., Urrutia, Y., Beltrán, I., Rossi, A. B., Lozano, H. Y., Guarín, J., & Losada-Barragán, M. (2020) · Figshare · doi:10.6084/m9.figshare.13173767
Aktuelle Therapiekonzepte und Entwicklungen in der Diabetes mellitus Typ 2-Therapie
Honskamp, A. K. (2021) · Unipub UB Graz (Universität Graz)
An investigation into approaches and pathways relevant to cellular flocculation in CHO cells
Berry, P. (2023) · Dublin City University Open Access Institutional Repository (Dublin City University)
Positron emission tomography imaging of disease activity in atherosclerosis
Virta, J. (2024) · UTUPub (University of Turku)
Li, S. Y., Sonti, A., Kaelber, D. C., Ben-Israel, D., Bowles, A., Reddy, D., & Kelly, M. L. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.111905 · Cited by 2
Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis
Park, B. (2025) · TSpace (University of Toronto)
Trabelsi, M.-S. (2015) · theses.fr (ABES) · doi:10.70675/57d5cdf4z352ez4ac4z9da1zee3dcc8aba01
“De plus, l’activation chronique du GLP-1R diminue l’infiltration des monocytes dans les aortes des souris ApoE-/- (Arakawa et al. 2010).”
BackgroundDépôts de graisse ectopique : étude de leur développement et de leur modulation
Abdesselam, I. (2016) · theses.fr (ABES) · doi:10.70675/1f016024z175cz4b35z8034za3b418cfe9c3 · Cited by 1
A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
Kordi, N., Kheirandish, R., Akraminia, P., Jung, F., & Karami, S. (2025) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291251414840
Developing treatment strategies to optimize outcomes in patients with psoriatic arthritis
Kharouf, F., Arraf, A., & Chandran, V. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2667340
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“At the cellular level, GLP-1 receptor activation has been shown to reduce monocyte adhesion to the vascular endothelium and limit macrophage infiltration into inflamed vascular tissues, attenuating early inflammatory events that contribute to cardiovascular pathology [173, 174].”
Exendin-4: Orchestrating Molecular Signals with Cellular Responses in Vascular Homeostasis.
Harbieh, I., Fahmy, E. K., Ismail, M. M., Padmanabha, B. V., Matar, A. A. M., Esmaeel, S. E., Rao, S. A. M., Alsel, B. T. A., & Elbana, A. K. (2026) · Journal of Pioneering Medical Science · doi:10.47310/jpms2026150509
“…switching [5,6] • Monocytes and Macrophages: High expression in these cells facilitates the anti-inflammatory and anti-atherogenic properties of GLP-1R agonists [7] Exendin-4 and Endothelial Function Endothelial dysfunction is characterized by reduced NO bioavailability and increased permeability.”
Corey, K., Nguyen, M., Mi, M. Y., Ramaker, M. E., Zhbannikov, I. Y., Sourij, H., Felker, G. M., Sattar, N. A., Green, J. B., Douglas, P. S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.204463
“Further studies have demonstrated improvement in systemic inflammation, endothelial function, and attenuation of platelet aggregation (13–15).”
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study
Wu, Y., Lin, Y. W., Wu, J., Zhao, L., Lin, Y. W., Chen, W., Zhu, Y., Wang, Y., Zhang, M., & Bao, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04469-8
“Although preclinical studies suggest that GLP-1RAs may inhibit eosinophil survival and activation via the PKA/NF-κB signaling pathway [32–34], the precise mechanisms in humans remain incompletely understood.”
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
Sato, T., Miyamoto, T., Fukuoka, R., Sugimoto, K., Tanimoto, Y., Nakayama, T., Tanimoto, K., Sugimura, K., Fujimoto, Y., & Kawamura, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70710
The perfusion-based model of AMD: Moving towards a unifying hypothesis
Holekamp, N. M., & Ivanova, S. I. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101507
Salaria, L., Pearce-Menzies, I., Mishra, A., Khan, S., Saravanan, P., Bhavsar, P. K., & Russomano, T. (2026) · Acta Astronautica · doi:10.1016/j.actaastro.2026.08.017
Exendin-4 as a multi-target therapy for Fetal Inflammatory Response Syndrome-induced brain injury
Li, S., Cai, C., & Arigong, G. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1848474
“This action effectively blocks the nuclear translocation of the NF-κ B p65 subunit and its binding to cognate DNA promoter sequences, thereby suppressing the transcriptional initiation of a wide array of pro-inflammatory genes (41).”
Glucagon-like peptide-1 improves mesangial proliferative glomerulonephritis in rats
Wang, X. Z., Wu, T., Tang, H. M., Deng, Y., & Li, C. H. (2018) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2018_042
Melnikov, I., Borodko, D. D., & Alekseev, V. (2026) · Cells · doi:10.3390/cells15171578
“In vivo [36] Liraglutide”
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Ramadan, A., Doma, M., Yazdanpanah, M. H., Naeem, F., Ptaszek, L. M., & Ruskin, J. N. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.09.018
Arecco, A., Piras, G., Cocchiara, F., Maggi, D. C., & Puddu, A. (2026) · Diabetology · doi:10.3390/diabetology7100187
Alharbi, N. H. J. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70329
Shoukry, H. S., Harbieh, I., Harbieh, M., Elbana, A. K., Fahmy, E. K., A, A. M. M., Esmaeel, S. E., Alruwaili, M. G., Rehman, A. G. A., Elshafey, S., et al. (2026) · Journal of Pioneering Medical Science · doi:10.47310/jpms2026150903
“This prevents the "velcro effect" where monocytes stick to vessel walls, effectively slowing plaque formation [6] • Oxidative Stress: Ex-4 enhances the activity of antioxidant enzymes like Superoxide Dismutase (SOD) via the Epac/Rap1 pathway, protecting cardiomyocytes from oxidative bursts during…”
InfluentialBerikkhanova, K., Inuwa, I., Sultan, Y., Berikkhanov, N., Rakhimova, S., & Akilzhanova, A. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208190
“Similarly, experimental studies in macrophages and atherosclerosis models have reported reduced inflammatory signalling and monocyte/macrophage accumulation following GLP-1R agonist treatment [66].”
de Nóbrega, C. S. F. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Filipe, J. F. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.